• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biogen Inc.

< Previous 1 2 3 4 Next >
News headline image
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SAGE
News headline image
Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
October 25, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
October 25, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB RETA
News headline image
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
September 25, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Appoints Jane Grogan as Head of Research
September 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Acquire Reata Pharmaceuticals
July 28, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB RETA
News headline image
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
July 19, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
July 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
June 30, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Announces Changes to Its Board of Directors
June 12, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
June 09, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
May 15, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
April 25, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Appoints Adam Keeney as Head of Corporate Development
April 04, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
March 30, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
March 29, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
March 22, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
March 16, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
March 08, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap